颅内肿瘤栓塞并发症:JR-NET2与JR-NET3比较
该研究比较日本神经血管内治疗登记JR-NET2与JR-NET3中颅内肿瘤栓塞的并发症发生率和危险因素。JR-NET2纳入1018例、JR-NET3纳入1545例连续患者。JR-NET3并发症发生率3.69%显著高于JR-NET2的1.48%(p=0.002);JR-NET3中非颈外动脉供血和液体材料使用是并发症的显著危险因素。
要点
- JR-NET3颅内肿瘤栓塞并发症发生率3.69%,显著高于JR-NET2的1.48%(p=0.002)。
- JR-NET3中非颈外动脉供血(OR 3.56;95%CI 2.03-6.25;p<0.001)与液体材料使用(OR 2.65;95%CI 1.50-4.68;p<0.001)为并发症显著危险因素。
- JR-NET2中非脑膜瘤肿瘤栓塞是唯一显著危险因素(OR 3.88;95%CI 1.13-12.10;p=0.032)。
核心结论
- JR-NET3中颅内肿瘤栓塞并发症发生率显著高于JR-NET2(3.69%对1.48%,p=0.002)。
- 非颈外动脉供血栓塞与液体材料使用可能增加颅内肿瘤栓塞的并发症率。
研究设计与样本
- 基于日本神经血管内治疗登记JR-NET2与JR-NET3的全国性调查比较分析。
- JR-NET2纳入1018例、JR-NET3纳入1545例连续接受栓塞治疗的颅内肿瘤患者。
- 比较两登记间颅内肿瘤栓塞并发症发生率及相关危险因素。
主要发现
- JR-NET3并发症发生率为3.69%,JR-NET2为1.48%(p=0.002)。
- JR-NET2多因素分析:非脑膜瘤肿瘤栓塞是唯一显著并发症危险因素(OR 3.88;95%CI 1.13-12.10;p=0.032)。
- JR-NET3多因素分析:非颈外动脉供血栓塞(OR 3.56;95%CI 2.03-6.25;p<0.001)与液体材料使用(OR 2.65;95%CI 1.50-4.68;p<0.001)为显著危险因素。
- JR-NET3非颈外动脉供血栓塞频率15.3%显著高于JR-NET2的9.2%(p<0.001)。
- 液体材料使用频率JR-NET3为41.2%,JR-NET2为21.2%,差异显著(p<0.001)。
临床怎么用
- 颅内肿瘤栓塞前应评估供血动脉来源,非颈外动脉供血者并发症风险较高。
- 使用液体栓塞材料时需权衡并发症风险并加强围术期监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Japanese Registry of NeuroEndovascular Therapy 2 (JR-NET2) and 3 (JR-NET3) were nationwide surveys that evaluated clinical outcomes after neuroendovascular therapy in Japan. The aim of this study was to compare the prevalence and risk factors of complications of intracranial tumor embolization between JR-NET2 and JR-NET3. METHODS: A total of 1018 and 1545 consecutive patients with intracranial tumors treated with embolization were enrolled in JR-NET2 and JR-NET3, respectively. The prevalence of complications in intracranial tumor embolization and related risk factors were compared between JR-NET2 and JR-NET3. RESULTS: The prevalence of complications in JR-NET3 (3.69%) was significantly higher than that in JR-NET2 (1.48%) (p = 0.002). The multivariate analysis in JR-NET2 showed that embolization for tumors other than meningioma was the only significant risk factor for complication (odds ratio [OR], 3.88; 95% confidence interval [CI], 1.13-12.10; p = 0.032), and that in JR-NET3 revealed that embolization for feeders other than external carotid artery (ECA) (OR, 3.56; 95% CI, 2.03-6.25; p < 0.001) and use of liquid materials (OR, 2.65; 95% CI, 1.50-4.68; p < 0.001) were significant risks for complications. The frequency of embolization for feeders other than ECA in JR-NET3 (15.3%) was significantly higher than that in JR-NET2 (9.2%) (p < 0.001). Also, there was a significant difference in the frequency of use of liquid materials between JR-NET2 (21.2%) and JR-NET3 (41.2%) (p < 0.001). CONCLUSIONS: Embolization for feeders other than ECA and use of liquid materials could increase the complication rate in intracranial tumor embolization.
引用
- Hishikawa T, Sugiu K, Murai S, et al. A comparison of the prevalence and risk factors of complications in intracranial tumor embolization between the Japanese Registry of NeuroEndovascular Therapy 2 (JR-NET2) and JR-NET3. Acta Neurochir (Wien). 2019. PMID: 31172282. doi:10.1007/s00701-019-03970-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。